Restructuring

9 Months Ended

Sep. 30, 2025

Restructuring and Related Activities [Abstract]

10.

Restructuring

The following table presents restructuring costs by segment as included within the Company’s unaudited condensed consolidated statements of operations for the periods reported (in millions):


	Three Months Ended September 30,					Nine Months Ended September 30,
	2025			2024		2025		2024
Cost of revenues:
BSI BioSpin	$	2.2		$	0.5	$	3.4	$	0.8
BSI CALID		12.5		—			14.3		0.8
BSI NANO		4.5			0.7		8.5		8.2
BEST		1.0		—			1.0	—
Total Cost of revenues	$	20.2		$	1.2	$	27.2	$	9.8
Other charges, net:
BSI BioSpin	$	2.1		$	1.2	$	5.4	$	1.4
BSI CALID		6.7			0.7		9.9		0.7
BSI NANO		5.2			1.2		8.0		5.2
BEST		0.4		—			0.4	—
Corporate		(0.1	)	—			1.1		0.5
Total Other charges, net		14.3			3.1		24.8		7.8
Total	$	34.5		$	4.3	$	52.0	$	17.6

The following table sets forth the changes in restructuring reserves, excluding costs of $16.4 million for scrapping expired or expiring inventory, for the periods reported (in millions):


	Total			Severance			Exit Costs
Balance at December 31, 2024	$	7.2		$	4.6		$	2.6
Restructuring charges		35.6			32.4			3.2
Cash payments		(17.8	)		(12.3	)		(5.5	)
Other, non-cash adjustments and foreign currency effect		0.8			0.8			—
Balance at September 30, 2025	$	25.8		$	25.5		$	0.3

Corporate wide restructuring plan: In the second quarter of 2025, the Company initiated a corporate-wide restructuring plan to be implemented across multiple functions and geographies to address current macroeconomic conditions and uncertainties challenges, drive cost efficiencies and margin improvements, as well as to address lower demand levels in certain of our product offerings. The restructuring plan includes a reduction in headcount, consolidation of leased facilities, and discontinuation of certain product offerings. The restructuring plan is expected to be completed during 2026.

The following table summarizes the charges incurred in connection with the corporate-wide restructuring plan by reportable segment for the periods reported (amounts in millions):


	Three Months Ended September 30, 2025			Nine Months Ended September 30, 2025
BSI BioSpin
Severance and termination charges	$	4.3		$	5.0
Total BSI BioSpin		4.3			5.0
BSI CALID
Severance and termination charges		8.2			9.1
Inventory product restructuring charges		10.9			10.9
Other restructuring charges		0.1			0.1
Total BSI CALID		19.2			20.1
BSI NANO
Severance and termination charges		8.7			10.7
Inventory product restructuring charges		0.8			0.8
Other restructuring charges		0.2			0.2
Total BSI NANO		9.7			11.7
BEST
Severance and termination charges		0.4			0.4
Inventory product restructuring charges		1.0			1.0
Total BEST		1.4			1.4
Corporate
Severance and termination charges		(0.1	)		1.1
Total Corporate		(0.1	)		1.1
Total Corporate wide restructuring charges (a)	$	34.5		$	39.3

The Company made severance, exit, and other restructuring payments of $3.8 million for the three and nine months ended September 30, 2025, respectively.

As of September 30, 2025, the Company expects to incur additional restructuring charges of $4.1 million in connection with this program through the remainder of 2025. However, there may be additional costs in addition to those known as of September 30, 2025 that will be recognized through the remainder of 2025 and 2026.

Bruker Cellular Analysis restructuring plan: The charges incurred by the Company in connection with the Bruker Cellular Analysis restructuring plan are summarized in the following table (amounts in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Severance and termination charges (a)	$	—	$	1.2	$	1.2	$	7.8
Product restructuring costs due to scrapping of expired or expiring inventory	$	—	$	4.7	$	—	$	4.7
Impairment charge against operating lease right of use assets	$	—	$	1.5	$	—	$	1.5

The Company made no severance payments during the three months ended September 30, 2025 and made severance payments of $3.7 million for the nine months ended September 30, 2025. The Company made severance payments of $2.8 million and $13.5 million during the three and nine months ended September 30, 2024, respectively.

Refer to Note 12, Restructurings and Asset Impairments of the Annual Report on Form 10-K for the year ended December 31, 2024 for further information on this restructuring plan.